Peptide– tag –
-
Entera Bio’s Oral Peptide Platform Advances to Phase 3 for Osteoporosis, Heralding a New Era for Injectable Therapeutics
Entera Bio, Inc. USA Overview Clinical-stage biopharmaceutical company Entera Bio has secured an agreement with the FDA to initiate a Phase 3 clinical trial for EB613, an oral parathyroid hormone (PTH) analog for postmenopausal osteoporo... -
CDMOs Accelerate GLP-1 Manufacturing, Outpacing Traditional Facility Builds to Meet Soaring Demand
Pharma Advancement USA Overview Contract Development and Manufacturing Organizations (CDMOs) are rapidly scaling their manufacturing capabilities for GLP-1 receptor agonists, providing quicker solutions than ground-up facility constructi... -
Oral GLP-1 Market Soars: Eli Lilly’s Foundayo and Novo Nordisk’s Oral Wegovy Reach New Prescription Highs
Fierce Pharma USA Overview Weekly prescriptions for Eli Lilly's oral GLP-1 agonist Foundayo and Novo Nordisk's oral Wegovy have reached new highs, demonstrating the significant impact of oral GLP-1 drugs on the obesity treatment landscap... -
China’s Ascletis Initiates Global Phase III for Oral GLP-1 Obesity Drug ASC30, Preclinical Triple Agonist FDC Shows Strong Weight Reduction
Ascletis (via news release) China Overview Chinese company Ascletis has initiated a global Phase III trial for its oral GLP-1 obesity drug, ASC30. Concurrently, the company announced positive preclinical data for its first-in-class, once... -
Swiss Bachem Invests Over $431M in 2026 to Meet Surging Global Peptide and Oligonucleotide Demand with New Facility
Pharma Manufacturing Switzerland Overview Bachem, a Swiss CDMO specializing in peptides and oligonucleotides, is undertaking a major manufacturing capacity expansion across its global network, investing between $431 million and $493 mill... -
Bioengineering Strategies Overcome Liver Tropism to Improve Cardiac Targeting of LNPs for Heart Disease Therapy
Arteriosclerosis, Thrombosis, and Vascular Biology - American Heart Association Journals USA Overview Despite promise in cardiovascular disease treatment, nanomedicines face challenges of insufficient cardiac targeting and poor retention... -
Frontiers in Nanotechnology Publishes Latest Open Access Research on Nanobiosensors, Gene Editing, and Nano-Vaccines
Frontiers in Nanotechnology International Overview The open-access journal "Frontiers in Nanotechnology" has published cutting-edge research across various applications of nanoscale science and engineering in medicine, environment, and i... -
Fujifilm Prepares for Patent Cliff with Strategic CDMO Investments; Samsung Biologics Acquires PolyPeptide for $1.8B, Entering Peptide Market
Endpoints News Global Overview The pharmaceutical industry faces a 'patent cliff' with ~$300 billion in branded drug revenues at risk from 2025-2030, driving active deals for portfolio expansion and cost efficiency. Contract Development ... -
Non-Endocytic Membrane-Translocating Delivery Strategies Bypass Endosomal Barriers for Gene, mRNA, and Protein Therapies
Drug Target Review UK Overview A new review evaluates non-endocytic membrane-translocating delivery strategies designed to circumvent insufficient endosomal escape efficiency, a major hurdle for many next-generation therapeutics. These e... -
Samsung Biologics Acquires PolyPeptide in All-Cash Offer: Accelerating Multi-Modality Strategy and Global Network Expansion
PR Newswire South Korea Overview Samsung Biologics announced an all-cash offer to acquire PolyPeptide, accelerating its multi-modality strategy and expanding its global manufacturing network across the U.S., Europe, and India. This acqui...
